You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
Bristol Myers Squibb
since
auto-detected in 15 stories
23 hours ago
Reports of preliminary talks between AstraZeneca and Bristol Myers Squibb moved shares and reignited debate over Big Pharma consolidation.
3 days ago
AstraZeneca investors raise concerns over mega-merger talks ⊖
Shareholders question looming patent cliff and antitrust risks in potential $400bn tie-up with Bristol Myers Squibb
4 days ago
AstraZeneca holds talks with Bristol Myers Squibb on $400bn merger ○
found
a story from The Guardian ⚠️ › International
Tie-up would be one of the biggest-ever pharmaceutical deals and create the world’s fourth-largest drugmaker
Business live – latest updates
Britain’s biggest drugmaker, AstraZeneca, is understood to be…
AstraZeneca holds talks with Bristol Myers Squibb over £300bn merger ○
found
a story from The Daily Mail 💩 › The Daily Mail
A deal by AstraZeneca chief executive Sir Pascal Soriot would extend the drugmaker's footprint in the US market.
AstraZeneca shares drop 7% after report on $400 billion merger talks with Bristol Myers Squibb ○
The companies have discussed a potential merger over several months, the Financial Times reported on Sunday.
AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports ○
U.K. pharmaceutical giant AstraZeneca is considering a deal to merge with its U.S. rival Bristol Myers Squibb.
AstraZeneca holds talks with Bristol Myers Squibb on $400bn megadeal ⊕
Tie-up would create one of the world’s biggest drugmakers
83 days ago
Bristol Myers Squibb turns to China to develop new drugs in newest cross-continent collaboration ○
found
U.S. drugmaker Bristol Myers Squibb inked a partnership with a Chinese company that some say could mark the next wave of collaboration across continents.
9 months ago
Healthy Returns: What to expect from Eli Lilly, Merck, Gilead and AbbVie third-quarter earnings ⊕
found
Eli Lilly, Merck, Gilead, Bristol Myers Squibb and AbbVie, among other pharmaceutical companies, are slated to report third-quarter earnings this week.
10 months ago
J&J's experimental psoriasis drug shows promise against Bristol's treatment ○
Johnson & Johnson said its experimental psoriasis drug has shown superior skin clearance compared to Bristol Myers Squibb's Sotyktu in two head-to-head trials.